Found 17 grace-kim-lee trials
A listing of grace-kim-lee medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
For subjects age 18 years and older who are at an increased risk for HCC and for whom HCC surveillance is appropriate, including subjects with cirrhosis or non-cirrhotic subjects with Hepatitis B. Approximately 3,000 subjects are expected to be enrolled, comprised of approximately 2,222 ultrasound surveillance subjects and 778 subjects …
A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC).
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome-Acute Kidney Injury
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects with Severe Alcohol-Associated Hepatitis.
The goal of study 1 and study 2 is to evaluate the effects of ALN-HSD on liver fibrosis and other histologic features of NASH in participants with NASH and F2/F3 fibrosis and risk alleles for HSD17B13. Necessary screening procedures include blood tests, liver stiffness measurement, study-specific genotype criteria, and a …
To evaluate the efficacy and safety of 2 different doses of daplusiran/tomligisiran (50 mg every 4 weeks and 200 mg every 4 weeks for a total of 6 doses) followed by bepirovirsen 300 mg weekly for 24 weeks (with loading doses) in people living with chronic HBV on nucleos(t)ide analogue …
Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease
Please see section 2 of the protocol, under "Introduction" for a list of study objectives. Please see section 2 of the protocol, under "Objectives" for a list of primary outcome variables. Please see section 2 of the protocol, under "Objectives" for a list of secondary outcome variables.
1 - 10 of 17
- 1
- 2
